IDH1 and neoplasm: Our analysis revealed that the low-score group had better prognosis, higher percentage of IDH mutation, MGMTp methylation, and1p/19q codeletion, and preferable antitumor therapy outcome, but lower tumor mutation burden (TMB), immune infiltration, and TMZ sensitivity.